Alembic Pharmaceuticals has officially incorporated a new subsidiary named Alembic Pharmaceuticals (Thailand) Co., Ltd in Thailand, as disclosed in its regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This strategic expansion represents the company's continued efforts to strengthen its global footprint in key Southeast Asian markets.

Financial Structure and Shareholding

The newly incorporated subsidiary has been established with specific financial parameters:

Strategic Business Objectives

According to the regulatory disclosure, the primary objective of establishing this subsidiary is to explore new business opportunities in the Thai geography. The company aims to promote, sell and distribute pharmaceutical products through this new entity, positioning Thailand as a strategic hub for regional operations.

Regulatory Compliance

The incorporation was formally communicated to both BSE Limited (Scrip Code: 533573) and National Stock Exchange of India Ltd (NSE Symbol: APLLTD) through proper regulatory channels. Company Secretary Manisha Saraf signed the disclosure documents, ensuring full compliance with listing obligations.

Market Expansion Strategy

This subsidiary establishment demonstrates Alembic Pharmaceuticals' proactive approach to international market development. Thailand represents a significant pharmaceutical market opportunity in Southeast Asia, offering potential for growth and enhanced competitive positioning in the global pharmaceutical landscape. The move aligns with the company's broader international expansion strategy to strengthen its presence in emerging markets.

Alembic Pharmaceuticals Limited announced a significant milestone with the first prescription-based sale of Pivya® (pivmecillinam) tablets in the United States following its recent commercial launch. This achievement marks the company's entry into the US branded pharmaceuticals market through its step-down wholly owned subsidiary, Alembic Therapeutics LLC.

Product Overview and Market Position

Pivya® represents Alembic's first branded pharmaceutical product in the US market, positioning the company in the specialty prescription segment. The oral prescription antibiotic is indicated as a first-line treatment for uncomplicated urinary tract infections (uUTIs) in women, addressing a therapeutic area that has experienced limited new product introductions for more than a decade.

Therapeutic Significance and Market Context

Uncomplicated urinary tract infections remain among the most common bacterial infections in women in the US, resulting in significant outpatient antibiotic prescription volumes annually. The therapeutic category represents a substantial and stable market, accounting for approximately 30 million prescriptions annually in the US.

Pivya® contains pivmecillinam, a beta-lactam antibacterial agent with an established international clinical history. The penicillin-class antibacterial is specifically indicated for female patients 18 years of age and older with uncomplicated urinary tract infections caused by susceptible isolates of:

• Escherichia coli
• Proteus mirabilis
• Staphylococcus saprophyticus

Strategic Leadership Perspective

Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, emphasized the strategic importance of this milestone: "The commercial launch of Pivya® marks an important milestone for Alembic as we enter the US branded pharmaceuticals market. What began as a strategic acquisition has now translated into a commercial presence in the specialty prescription segment."

He further outlined the company's broader vision: "Pivya® represents the first step in Alembic's strategy to build a focused branded specialty portfolio in the US, enabling us to participate in a large and stable therapeutic category with a clinically established and differentiated product. Over time, we intend to leverage this platform to build a broader branded portfolio in the US market."

Commercial Strategy and Market Approach

Alembic has established an initial sales footprint across key territories in the US, with each territory focusing on high-prescribing physicians in women's health and engaging a targeted base of prescribers. The company plans a phased expansion of its field force as prescription momentum builds, supported by targeted physician education and market access initiatives.

The launch strategy emphasizes appropriate antibiotic stewardship and positions pivmecillinam as an important tool in managing uncomplicated urinary tract infections, particularly given the increasing emphasis on effective first-line therapies.

Strategic Context and Future Outlook

This development represents an important step in Alembic's broader US market strategy, which encompasses a balanced approach across generics, specialty products, and branded pharmaceuticals. The Pivya® launch establishes a branded business platform in the US that complements the company's established generics franchise.

Alembic continues its commitment to disciplined investments supporting sustainable growth and long-term value creation in one of the world's largest pharmaceutical markets. The company's vertically integrated research and development capabilities, combined with USFDA-approved manufacturing facilities, provide a strong foundation for this branded pharmaceuticals initiative.